BioStock: Spago Nanomedical prepares for an eventful 2022
Lund-based Spago Nanomedical has completed the pre-clinical programme with SN201, the candidate drug in the cancer treatment project Tumorad. Reaching this milestone,together with the completion of the second cohort in the SPAGOPIX-01 study, the company ends the year on a high note as it prepares for an eventful 2022. BioStock reached out to CEO Mats Hansen to find out more.Read the interview with Spago Nanomedical's CEO Mats Hansen at biostock.se: https://www.biostock.se/en/2021/12/spago-nanomedical-prepares-for-an-eventful-2022/ This is a press release from BioStock - Connecting